- Home
- REFI vs STRO Comparison
REFI vs STRO Comparison
Compare REFI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- STRO
- Stock Information
- Founded
- REFI 2021
- STRO 2003
- Country
- REFI United States
- STRO United States
- Employees
- REFI N/A
- STRO N/A
- Industry
- REFI Real Estate Investment Trusts
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REFI Real Estate
- STRO Health Care
- Exchange
- REFI Nasdaq
- STRO Nasdaq
- Market Cap
- REFI 274.3M
- STRO 74.3M
- IPO Year
- REFI 2021
- STRO 2018
- Fundamental
- Price
- REFI $13.45
- STRO $0.85
- Analyst Decision
- REFI Strong Buy
- STRO Hold
- Analyst Count
- REFI 3
- STRO 7
- Target Price
- REFI $20.00
- STRO $1.97
- AVG Volume (30 Days)
- REFI 129.1K
- STRO 520.3K
- Earning Date
- REFI 11-06-2025
- STRO 11-12-2025
- Dividend Yield
- REFI 15.24%
- STRO N/A
- EPS Growth
- REFI N/A
- STRO N/A
- EPS
- REFI 1.84
- STRO N/A
- Revenue
- REFI $56,608,781.00
- STRO $104,473,000.00
- Revenue This Year
- REFI $9.93
- STRO $65.48
- Revenue Next Year
- REFI $4.99
- STRO N/A
- P/E Ratio
- REFI $7.36
- STRO N/A
- Revenue Growth
- REFI 2.58
- STRO N/A
- 52 Week Low
- REFI $12.76
- STRO $0.52
- 52 Week High
- REFI $16.29
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- REFI 41.94
- STRO 45.04
- Support Level
- REFI $13.08
- STRO $0.85
- Resistance Level
- REFI $14.57
- STRO $1.01
- Average True Range (ATR)
- REFI 0.33
- STRO 0.09
- MACD
- REFI -0.10
- STRO -0.01
- Stochastic Oscillator
- REFI 24.83
- STRO 5.30
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.